Amgen (AMGN)
(Delayed Data from NSDQ)
$319.04 USD
+7.63 (2.45%)
Updated May 15, 2024 04:00 PM ET
After-Market: $319.04 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$319.04 USD
+7.63 (2.45%)
Updated May 15, 2024 04:00 PM ET
After-Market: $319.04 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Amgen (AMGN) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Amgen (AMGN) delivered earnings and revenue surprises of 1.07% and 1%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stocks' Q4 Earnings Due on Feb 6: AMGN, LLY & More
by Zacks Equity Research
Let's take a look at four biotech, drug companies, AMGN, LLY, GILD and EXEL, slated to release quarterly results on Feb 6.
Take the Zacks Approach to Beat the Market: NVIDIA, Carrols, CyberArk in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
AbbVie (ABBV) Q4 Earnings Beat, Raises Sales View for Key Drugs
by Zacks Equity Research
AbbVie???s (ABBV) fourth-quarter earnings and sales beat estimates. Management hikes the 2027 forecast for new immunology drugs to more than $27 billion.
Unlocking Q4 Potential of Amgen (AMGN): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Amgen (AMGN) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Amgen (AMGN) Stock Moves -0.11%: What You Should Know
by Zacks Equity Research
Amgen (AMGN) reachead $314.26 at the closing of the latest trading day, reflecting a -0.11% change compared to its last close.
Eli Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Eli Lilly's (LLY) fourth-quarter conference call, investor focus is likely to be on the sales performance of its tirzepatide medicines, Mounjaro and Zepbound.
Regeneron (REGN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when Regeneron (REGN) reports its fourth-quarter 2023 results.
Will Amazon's (AMZN) Q4 Earnings Benefit From AWS Momentum?
by Zacks Equity Research
Amazon's (AMZN) fourth-quarter results are likely to reflect benefits from AWS' expanding customer base, driven by the strong services portfolio and rising number of cloud regions.
Amgen (AMGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Can Amgen (AMGN) Keep the Beat Streak Alive in Q4 Earnings?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Key Takeaways From JNJ's (JNJ) Q4 Earnings Presentation
by Zacks Equity Research
J&J's (JNJ) Innovative Medicines as well as MedTech units outperform expectations in the fourth quarter. Here we discuss some highlights of its performance in the fourth quarter.
Amgen (AMGN) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $310.26, marking a +1.56% move from the previous day.
Amgen Inc. (AMGN) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Amgen (AMGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHD
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
The Zacks Analyst Blog Highlights Novartis, Amgen, Palo Alto, Brown & Brown and Ericsson
by Zacks Equity Research
Novartis, Amgen, Palo Alto, Brown & Brown and Ericsson are included in this Analyst Blog.
Top Research Reports for Novartis, Amgen & Palo Alto Networks
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), Amgen Inc. (AMGN) and Palo Alto Networks, Inc. (PANW).
Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy
by Zacks Equity Research
Verastem's (VSTM) avutometinib/Lumakras combination therapy gets the FDA's Fast Track designation to treat KRAS G12C-mutant metastatic NSCLC patients. The stock gains 8% in response.
Here's Why Amgen (AMGN) Gained But Lagged the Market Today
by Zacks Equity Research
Amgen (AMGN) reachead $307.81 at the closing of the latest trading day, reflecting a +1.09% change compared to its last close.
Amgen (AMGN) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $304.08, moving +0.2% from the previous trading session.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.